Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Virotherapy
100%
MV-NIS
100%
Measles
100%
Multiple Myeloma
100%
Virus
61%
Myeloma
45%
Antimeasles Antibody
32%
Radiovirotherapy
32%
Cyclophosphamide
24%
Radioiodine Imaging
21%
Antibody Response
21%
I-131
21%
Clinical Trials
13%
Oncolytic Measles Virus
13%
Phase I Trial
10%
Antibody Titer
10%
Mouse Data
10%
Immune Response
10%
Intravenous Delivery
10%
Dosimetry Calculations
10%
High Dose
10%
Relapsed/refractory multiple Myeloma
10%
Radioiodine
10%
Tumor-bearing Mice
10%
Manufacturing Methods
10%
Imaging Studies
10%
Minimum Effective Dose
10%
Site of Disease
10%
Advanced Treatment
10%
As(III)
10%
Treatment Refractory
10%
Anamnestic
10%
TCID50
10%
Thyroid Gland
10%
Disseminated Infection
10%
Mice Experiment
10%
Tumor Growth
10%
Well Tolerated
10%
Clinical Protocols
10%
Antitumor Efficacy
10%
Safety/tolerability
10%
Repeated Dosing
10%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Measles
100%
Virotherapy
100%
Virus
100%
Myeloma
93%
Radioactive Iodine
54%
Clinical Trial
39%
Cyclophosphamide
39%
Iodine-131
36%
Measles Virus
21%
Tumor Growth
18%
Administered Dose
18%
Tolerability
18%
Dosimetry
18%
Minimal Effective Dose
18%
Neoplasm
18%
Diseases
18%
Immunology and Microbiology
Virotherapy
75%
Virus
75%
Multiple Myeloma
75%
Measles
75%
Cyclophosphamide
30%
Iodine-131
30%
Antibody Response
30%
Thyroid
30%
Drug Megadose
15%
Measles Virus
15%
Immune Response
15%
Antibody Titer
15%